Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Hinge Health, Inc.

$68.74

+0.92 (+1.36%)

F 17Pipeline Score Tools & Services · Clinical
Market Cap
2.79 B
EPS
-5.44
P/E Ratio
-6.5 $
Value Trade
58.24 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    182.31 M

  • R&D Expenses

    30.34 M

  • Operating CF

    43.08 M

  • Total Assets

    728.77 M

  • Total Liabilities

    417.21 M

  • Equity

    111.69 M

  • D/E Ratio

    12,345

%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Profitable

  • Cash Position

    315.87 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
281.67 K
52 Week Range
30.08 - 62.18
% held by Insiders
70.51 %
% held by Institutions
52.67 %
Enterprise Value
2.63 B
Total Shares
54.65 M
Short %
9.86 %
Float Shares
41.04 M
Company Description
HQ: 455 MARKET STREET, SAN FRANCIS...
Employees:1,437
https://www.hingehealth.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
F17
Pipeline Score
-
Pipeline Value
Valuation Signal
0
Drugs Scored
—
rNPV / MCap
Top 15%
Small Cap
(rank 770 of 905)
Percentile Rank
Hinge Health, Inc. has significant pipeline risk (17/100).
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in HNGE
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Hinge Health, Inc. (HNGE) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
HNGE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HNGE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HNGE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
HNGE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
HNGE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HNGE
Jun 10, 2026
HNGEGeneral

Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform

Hinge Health has expanded its HingeSelect platform to include surgical options, enhancing its integrated musculoskeletal care offerings. This development aims to provide comprehensive care solutions for patients. The addition signifies Hinge Health's commitment to improving patient outcomes through a more holistic approach to musculoskeletal health.

Read more →
-HNGE
Jun 9, 2026
HNGEGeneral

Hinge Health hosts its first Investor Day and raises guidance

Hinge Health recently hosted its inaugural Investor Day, where it provided updates on its business performance and future outlook. The company raised its guidance, indicating a positive trajectory in its operations. However, specific details regarding the financial implications were not disclosed in the article.

Read more →
-HNGE
Jun 3, 2026
HNGEGeneral

Hinge Health proven to deliver 3.0x ROI with the largest study of its kind

Hinge Health has conducted the largest study of its kind, demonstrating a 3.0x return on investment (ROI). The details of the study and its implications for the company's future performance are not provided in the article. The findings may influence stakeholders' perception of Hinge Health's value in the market.

Read more →
-HNGE
May 5, 2026
HNGEGeneral

Hinge Health reports record first quarter 2026 financial results

Hinge Health has announced its financial results for the first quarter of 2026, reporting record figures. The announcement highlights the company's growth and performance during this period. However, specific financial details and metrics were not provided in the article.

Read more →
-HNGE
Apr 29, 2026
HNGEGeneral

Hinge Health launches comprehensive Migraine Care Program

Hinge Health has launched a new Migraine Care Program aimed at providing drug-free pain relief and personalized management for migraine sufferers. The program utilizes the FDA-cleared Enso device, which offers rapid pain relief, alongside AI-powered insights for trigger management. With a focus on proactive prevention through exercise therapy, the program is set to roll out in May 2026 and has already gained significant employer interest.

Read more →
Competitive Position
How HNGE ranks across every disease it competes in
Competitive Position is a premium feature
See how HNGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial